In October 2022, President Joko Widodo announced that Bio Farma will produce up to 20 million doses of the vaccine for the initial first phase of production in the same year. The production capacity will be increased to 40 million doses in 2023.[1]
In October 2022, President Joko Widodo announced that Bio Farma will produce up to 20 million doses of the vaccine for the initial first phase of production in the same year. The production capacity will be increased to 40 million doses in 2023.[1]